Type B coxsackieviruses and their interactions with the innate and adaptive immune systems

Future Microbiology

Volumn 5, Issue 9, 2010, Pages 1329-1347

  Kemball, Christopher C ^a   Alirezaei, Mehrdad ^a   Whitton, J Lindsay ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

adaptive immunity; autophagy; coxsackievirus; innate immunity; loop pathogenesis; mitochondria; picornavirus; RIG I like recepto; T cell; Toll like receptor

Indexed keywords

PROTEIN KINASE R; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VIRUS RNA;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; AUTOIMMUNITY; AUTOPHAGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; COXSACKIE VIRUS B; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; T-LYMPHOCYTES;

COXSACKIEVIRUS; PICORNAVIRIDAE;

EID: 77957593459     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.101     Document Type: Review

References (209)

1. Modlin JF, Rotbart HA: Group B coxsackie disease in children. Curr. Top. Microbiol. Immunol. 223, 53-80 (1997).
2. Whitton JL: Immunopathology during coxsackievirus infection. Springer Semin. Immunopathol. 24, 201-213 (2002)
3. Romero JR: Pediatric group B coxsackievirus infections. Curr. Top. Microbiol. Immunol. 323, 223-239 (2008).
4. OConnell JB: The role of myocarditis in end-stage dilated cardiomyopathy. Tex. Heart Inst. J. 14, 268-275 (1987).
5. Sole MJ, Liu P: Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 22, A99-A105 (1993).
6. Tam PE: Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 19, 133-146 (2006).
7. Daley AJ, Isaacs D, Dwyer DE, Gilbert GL: A cluster of cases of neonatal coxsackievirus B meningitis and myocarditis. J. Paediatr. Child Health 34, 196-198 (1998).
8. Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL: Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology 271, 276-288 (2000).
9. Huber S, Ramsingh AI: Coxsackievirus-induced pancreatitis. Viral Immunol. 17, 358-369 (2004).
10. Feuer R, Pagarigan RR, Harkins S, Liu F, Hunziker IP, Whitton JL: Coxsackievirus targets proliferating neuronal progenitor cells in the neonatal CNS. J. Neurosci. 25, 2434-2444 (2005).
11. Beutler B: Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol. Rev. 227, 248-263 (2009).
12. Kurt-Jones EA, Popova L, Kwinn L et al.: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398-401 (2000).
13. Georgel P, Jiang Z, Kunz S et al.: Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362, 304-313 (2007).
14. Triantafilou K, Triantafilou M: Coxsackievirus B4-induced cytokine production in pancreatic cells is mediated through toll-like receptor 4. J. Virol. 78, 11313-11320 (2004).
15. Fairweather D, Yusung S, Frisancho S et al.: IL-12 receptor b 1 and Toll-like receptor 4 increase IL-1 b-and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol. 170, 4731-4737 (2003).
16. Frisancho-Kiss S, Davis SE, Nyland JF et al.: Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol. 178, 6710-6714 (2007).
17. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR: LPS promotes CB3-induced myocarditis in resistant B10.A mice. Cell Immunol. 136, 219-233 (1991).
18. Richer MJ, Fang D, Shanina I, Horwitz MS: Toll-like receptor 4-induced cytokine production circumvents protection conferred by TGF-b in coxsackievirus-mediated autoimmune myocarditis. Clin. Immunol. 121(3), 339-349 (2006).
19. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413, 732-738 (2001).
20. Negishi H, Osawa T, Ogami K et al.: A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc. Natl Acad. Sci. USA 105, 20446-20451 (2008).
21. Weinzierl AO, Szalay G, Wolburg H et al.: Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4-/ CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. J. Virol. 82, 8149-8160 (2008).
22. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS: Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS ONE 4, E4127 (2009).
23. Triantafilou K, Orthopoulos G, Vakakis E et al.: Human cardiac inflammatory responses triggered by coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell. Microbiol. 7, 1117-1126 (2005).
24. Heil F, Hemmi H, Hochrein H et al.: Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
25. Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH: A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol. Immunol. 47, 1083-1090 (2010)
26. Werling D, Jann OC, Offord V, Glass EJ, Coffey TJ: Variation matters: TLR structure and species-specific pathogen recognition. Trends Immunol. 30, 124-130 (2009).
27. Berdeli A, Celik HA, Ozyurek R, Dogrusoz B, Aydin HH: TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J. Mol. Med. 83, 535-541 (2005).
28. Tuthill TJ, Bubeck D, Rowlands DJ, Hogle JM: Characterization of early steps in the poliovirus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles. J. Virol. 80, 172-180 (2006).
29. Brandenburg B, Lee LY, Lakadamyali M, Rust MJ, Zhuang X, Hogle JM: Imaging poliovirus entry in live cells. PLoS Biol. 5, E183 (2007).
30. Milstone AM, Petrella J, Sanchez MD, Mahmud M, Whitbeck JC, Bergelson JM: Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate. J. Virol. 79, 655-660 (2005).
31. Coyne CB, Bergelson JM: Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124, 119-131 (2006).
32. Coyne CB, Shen L, Turner JR, Bergelson JM: Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe 2, 181-192 (2007).
33. Patel KP, Coyne CB, Bergelson JM: Dynamin-and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. J. Virol. 83, 11064-11077 (2009).
34. Wang JP, Asher DR, Chan M, Kurt-Jones EA, Finberg RW: Cutting edge: antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol. 178, 3363-3367 (2007).
35. Deretic V: Autophagy in infection. Curr. Opin. Cell Biol. 22(2), 252-262 (2010).
36. Deretic V, Levine B: Autophagy, immunity, and microbial adaptations. Cell Host Microbe 5, 527-549 (2009).
37. Orvedahl A, Macpherson S, Sumpter R Jr, Talloczy Z, Zou Z, Levine B: Autophagy protects against sindbis virus infection of the central nervous system. Cell Host Microbe 7, 115-127 (2010).
38. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A: Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315, 1398-1401 (2007).
39. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V: Toll-like receptors control autophagy. EMBO J. 27, 1110-1121 (2008).
40. Dales S, Eggers HJ, Tamm I, Palade GE: Electron microscopic study of the formation of poliovirus. Virology 26, 379-389 (1965).
41. Schlegel A, Giddings TH Jr, Ladinsky MS, Kirkegaard K: Cellular origin and ultrastructure of membranes induced during poliovirus infection. J. Virol. 70, 6576-6588 (1996).
42. Suhy DA, Giddings TH Jr, Kirkegaard K: Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J. Virol. 74, 8953-8965 (2000).
43. Taylor MP, Kirkegaard K: Potential subversion of autophagosomal pathway by picornaviruses. Autophagy 4, 286-289 (2008).
44. Taylor MP, Kirkegaard K: Modification of cellular autophagy protein LC3 by poliovirus. J. Virol. 81, 12543-12553 (2007).
45. Harb JM, Burch GE: Spherical aggregates of coxsackie B4 virus particles in mouse pancreas. Beitr. Pathol. 156, 122-127 (1975).
46. Wong J, Zhang J, Si X et al.: Autophagosome supports coxsackievirus B3 replication in host cells. J. Virol. 82, 9143-9153 (2008).
47. Yoon SY, Ha YE, Choi JE et al.: Coxsackievirus B4 uses autophagy for replication after calpain activation in rat primary neurons. J. Virol. 82, 11976-11978 (2008).
48. Jackson WT, Giddings TH Jr, Taylor MP et al.: Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 3, e156 (2005).
49. Zhou Z, Jiang X, Liu D et al.: Autophagy is involved in influenza A virus replication. Autophagy 5, 321-328 (2009).
50. Sir D, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH: The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc. Natl Acad. Sci. USA 107, 4383-4388 (2010).
51. Dreux M, Gastaminza P, Wieland SF, Chisari FV: The autophagy machinery is required to initiate hepatitis C virus replication. Proc. Natl Acad. Sci. USA 106, 14046-14051 (2009).
52. Wileman T: Aggresomes and autophagy generate sites for virus replication. Science 312, 875-878 (2006).
53. Taylor MP, Jackson WT: Viruses and arrested autophagosome development. Autophagy 5, 870-871 (2009).
54. Taylor MP, Burgon TB, Kirkegaard K, Jackson WT: Role of microtubules in extracellular release of poliovirus. J. Virol. 83, 6599-6609 (2009).
55. Gannage M, Dormann D, Albrecht R et al.: Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 6, 367-380 (2009).
56. Kyei GB, Dinkins C, Davis AS et al.: Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J. Cell Biol. 186, 255-268 (2009).
57. de Bouteiller O, Merck E, Hasan UA et al.: Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 280, 38133-38145 (2005).
58. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL: UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452, 234-238 (2008).
59. Serresi M, Bizzarri R, Cardarelli F, Beltram F: Real-time measurement of endosomal acidification by a novel genetically encoded biosensor. Anal. Bioanal. Chem. 393, 1123-1133 (2009).
60. Lee J, Chuang TH, Redecke V et al.: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl Acad. Sci. USA 100, 6646-6651 (2003).
61. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
62. Latz E, Schoenemeyer A, Visintin A et al.: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5, 190-198 (2004).
63. Rutz M, Metzger J, Gellert T et al.: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner. Eur. J. Immunol. 34, 2541-2550 (2004).
64. Sepulveda FE, Maschalidi S, Colisson R et al.: Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 31, 737-748 (2009)
65. Luber CA, Cox J, Lauterbach H et al.: Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 32, 279-289 (2010).
66. Mukherjee A, Morosky SA, Shen L et al.: Retinoic acid-induced gene-1 (RIG-I) associates with the actin cytoskeleton via caspase activation and recruitment domain-dependent interactions. J. Biol. Chem. 284, 6486-6494 (2009).
67. Kato H, Takeuchi O, Sato S et al.: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
68. Loo YM, Fornek J, Crochet N et al.: Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82, 335-345 (2008).
69. Dixit E, Boulant S, Zhang Y et al.: Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141, 668-681 (2010).
70. Seth RB, Sun L, Ea CK, Chen ZJ: Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF 3. Cell 122, 669-682 (2005).
71. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB: VISA is an adapter protein required for virus-triggered IFN-b signaling. Mol. Cell 19, 727-740 (2005).
72. Meylan E, Curran J, Hofmann K et al.: Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
73. Kawai T, Takahashi K, Sato S et al.: IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
74. Hornung V, Ellegast J, Kim S et al.: 5-triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).
75. Pichlmair A, Schulz O, Tan CP et al.: RIG-I-mediated antiviral responses to single-stranded RNA bearing 5-phosphates. Science 314, 997-1001 (2006).
76. Barral PM, Sarkar D, Fisher PB, Racaniello VR: RIG-I is cleaved during picornavirus infection. Virology 391, 171-176 (2009).
77. Coyne CB, Kim KS, Bergelson JM: Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2. EMBO J. 26, 4016-4028 (2007).
78. Ju Y, Wang T, Li Y, Xin W, Wang S, Li J: Coxsackievirus B3 affects endothelial tight junctions: possible relationship to ZO-1 and F-actin, as well as p38 MAPK activity. Cell Biol. Int. 31, 1207-1213 (2007).
79. Gitlin L, Barchet W, Gilfillan S et al.: Essential role of MDA-5 in type I IFN responses to poly riboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103, 8459-8464 (2006).
80. Fredericksen BL, Gale M Jr: West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J. Virol. 80, 2913-2923 (2006).
81. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr: Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82, 609-616 (2008).
82. Kato H, Takeuchi O, Mikamo-Satoh E et al.: Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205, 1601-1610 (2008).
83. Yount JS, Gitlin L, Moran TM, Lopez CB: MDA5 participates in the detection of paramyxovirus infection and is essential for the early activation of dendritic cells in response to Sendai virus defective interfering particles. J. Immunol. 180, 4910-4918 (2008).
84. Gitlin L, Benoit L, Song C et al.: Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS Path. 6, E1000734 (2010).
85. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin HW, Colonna M: MDA-5 recognition of a murine norovirus. PLoS Path. 4, E1000108 (2008).
86. Ikegame S, Takeda M, Ohno S, Nakatsu Y, Nakanishi Y, Yanagi Y: Both RIG-I and MDA5 RNA helicases contribute to the induction of a/b interferon in measles virus-infected human cells. J. Virol. 84, 372-379 (2010).
87. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW: MDA5 and MAVS mediate type I IFN responses to coxsackie B virus. J. Virol. 84, 254-260 (2010).
88. Huhn MH, McCartney SA, Lind K, Svedin E, Colonna M, Flodstrom-Tullberg M: Melanoma differentiation-associated protein-5 (MDA-5) limits early viral replication but is not essential for the induction of type 1 interferons after coxsackievirus infection. Virology 401, 42-48 (2010).
89. Barral PM, Morrison JM, Drahos J et al.: MDA-5 is cleaved in poliovirus-infected cells. J. Virol. 81, 3677-3684 (2007).
90. Saito T, Hirai R, Loo YM et al.: Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl Acad. Sci. USA 104, 582-587 (2007).
91. Komuro A, Horvath CM: RNA-and virus-independent inhibition of antiviral signaling by RNA helicase LGP2. J. Virol. 80, 12332-12342 (2006).
92. Rothenfusser S, Goutagny N, DiPerna G et al.: The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 175, 5260-5268 (2005).
93. Venkataraman T, Valdes M, Elsby R et al.: Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J. Immunol. 178, 6444-6455 (2007).
94. Satoh T, Kato H, Kumagai Y et al.: LGP2 is a positive regulator of RIG-I-and MDA5-mediated antiviral responses. Proc. Natl Acad. Sci. USA 107, 1512-1517 (2010).
95. Kramer M, Schulte BM, Toonen LW et al.: Echovirus infection causes rapid loss-of-function and cell death in human dendritic cells. Cell. Microbiol. 9, 1507-1518 (2007).
96. Kramer M, Schulte BM, Toonen LW et al.: Phagocytosis of picornavirus-infected cells induces an RNA-dependent antiviral state in human dendritic cells. J. Virol. 82, 2930-2937 (2008).
97. Sun Q, Sun L, Liu HH et al.: The specific and essential role of MAVS in antiviral innate immune responses. Immunity 24, 633-642 (2006).
98. Yang Y, Liang Y, Qu L et al.: Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl Acad. Sci. USA 104, 7253-7258 (2007).
99. Lei Y, Moore CB, Liesman RM et al.: MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS ONE 4, E5466 (2009).
100. Yu CY, Chiang RL, Chang TH, Liao CL, Lin YL: The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting the mitochondrial membrane potential and by activating caspases. J. Virol. 84, 2421-2431 (2010).
101. Castanier C, Garcin D, Vazquez A, Arnoult D: Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep. 11, 133-138 (2010).
102. Deane JA, Pisitkun P, Barrett RS et al.: Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27, 801-810 (2007).
103. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
104. Perl A, Nagy G, Gergely P, Puskas F, Qian Y, Banki K: Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol. Med. 102, 87-114 (2004).
105. Jonsen A, Yu X, Truedsson L et al.: Mitochondrial DNA polymorphisms are associated with susceptibility and phenotype of systemic lupus erythematosus. Lupus 18, 309-312 (2009).
106. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW: Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to coxsackievirus B3-induced myocarditis. J. Immunol. 138, 2488-2492 (1987).
107. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW: Cardiac myosin induces myocarditis in genetically predisposed mice. J. Immunol. 139, 3630-3636 (1987).
108. Rose NR, Herskowitz A, Neumann DA: Autoimmunity in myocarditis: models and mechanisms. Clin. Immunol. Immunopathol. 68, 95-99 (1993).
109. Huber SA, Lodge PA: Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am. J. Pathol. 116, 21-29 (1984).
110. Huber SA, Lyden DC, Lodge PA: Immunopathogenesis of experimental coxsackievirus induced myocarditis: role of autoimmunity. Herz 10, 1-7 (1985).
111. Estrin M, Smith C, Huber SA: Coxsackievirus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment. Am. J. Pathol. 125, 244-251 (1986).
112. Smyth DJ, Cooper JD, Bailey R et al.: A genome-wide association study of nonsynonymous SNPs identifies a Type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38, 617-619 (2006).
113. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA: Rare variants of IFIH1, a gene implicated in antiviral responses, protect against Type 1 diabetes. Science 324, 387-389 (2009).
114. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T: Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J. Biol. Chem. 284, 13348-13354 (2009).
115. Hultcrantz M, Huhn MH, Wolf M et al.: Interferons induce an antiviral state in human pancreatic islet cells. Virology 367(1), 92-101 (2007).
116. Schlee M, Barchet W, Hornung V, Hartmann G: Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids. Curr. Top. Microbiol. Immunol. 316, 207-230 (2007).
117. Ward SV, Samuel CE: Regulation of the interferon-inducible PKR kinase gene: the KCS element is a constitutive promoter element that functions in concert with the interferon-stimulated response element. Virology 296, 136-146 (2002).
118. Vella C, Festenstein H: Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. J. Gen. Virol. 73(Pt 6), 1379-1386 (1992).
119. Yuan J, Liu Z, Lim T et al.: CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ. Res. 104(5), 628-638 (2009).
120. Seko Y, Shinkai Y, Kawasaki A et al.: Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 84, 788-795 (1991).
121. Henke A, Huber SA, Stelzner A, Whitton JL: The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69, 6720-6728 (1995).
122. Godeny EK, Gauntt CJ: Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis. J. Immunol. 137, 1695-1702 (1986).
123. Godeny EK, Gauntt CJ: Murine natural killer cells limit coxsackievirus B3 replication. J. Immunol. 139, 913-918 (1987).
124. Cornell CT, Kiosses WB, Harkins S, Whitton JL: Inhibition of protein trafficking by coxsackievirus B3: multiple viral proteins target a single organelle. J. Virol. 80, 6637-6647 (2006).
125. Cornell CT, Kiosses WB, Harkins S, Whitton JL: Coxsackievirus B3 proteins directionally complement each other to downregulate surface MHC class I. J. Virol. 81, 6785-6797 (2007).
126. Huhn MH, Hultcrantz M, Lind K, Ljunggren HG, Malmberg KJ, Flodstrom-Tullberg M: IFN-g production dominates the early human natural killer cell response to coxsackievirus infection. Cell. Microbiol. 10, 426-436 (2008).
127. Bruton OC: Agammaglobulinemia. Pediatrics 9, 722-728 (1952).
128. Good RA, Zak SJ: Disturbance in g-globulin synthesis as experiments of nature. Pediatrics 18, 109-149 (1956).
129. Dörries R, ter Meulen V: Specificity of IgM antibodies in acute human coxsackievirus B infections, analysed by indirect solid phase enzyme immunoassay and immunoblot technique. J. Gen. Virol. 64(Pt 1), 159-167 (1983).
130. Lodge PA, Herzum M, Olszewski J, Huber SA: Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am. J. Pathol. 128, 455-463 (1987).
131. Sauter P, Hober D: Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 11, 443-451 (2009).
132. Haarmann CM, Schwimmbeck PL, Mertens T, Schultheiss HP, Strauer BE: Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Virology 200, 381-389 (1994).
133. Leipner C, Borchers M, Merkle I, Stelzner A: Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. J. Hum. Virol. 2, 102-114 (1999).
134. Hashimoto I, Komatsu T: Myocardial changes after infection with coxsackie virus B3 in nude mice. Br. J. Exp. Pathol. 59, 13-20 (1978).
135. Woodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J. Immunol. 113, 1726-1734 (1974).
136. Huber SA, Pfaeffle B: Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 68, 5126-5132 (1994).
137. Cooper JB, Pratt WR, English BK, Shearer WT: Coxsackievirus B3 producing fatal meningoencephalitis in a patient with X-linked agammaglobulinemia. Am. J. Dis. Child 137, 82-83 (1983).
138. Hertel NT, Pedersen FK, Heilmann C: Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia. Eur. J. Pediatr. 148, 642-643 (1989).
139. Katamura K, Hattori H, Kunishima T, Kanegane H, Miyawaki T, Nakahata T: Non-progressive viral myelitis in X-linked agammaglobulinemia. Brain Dev. 24, 109-111 (2002)
140. Misbah SA, Spickett GP, Ryba PC et al.: Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J. Clin. Immunol. 12, 266-270 (1992).
141. Johnson JP, Yolken RH, Goodman D, Winkelstein JA, Nagel JE: Prolonged excretion of group A coxsackievirus in an infant with agammaglobulinemia. J. Infect. Dis. 146, 712 (1982).
142. ONeil KM, Pallansch MA, Winkelstein JA, Lock TM, Modlin JF: Chronic group A coxsackievirus infection in agammaglobulinemia: demonstration of genomic variation of serotypically identical isolates persistently excreted by the same patient. J. Infect. Dis. 157, 183-186 (1988).
143. Kew OM, Sutter RW, Nottay BK et al.: Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36, 2893-2899 (1998).
144. Martin J, Odoom K, Tuite G et al.: Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78, 13839-13847 (2004).
145. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard JR, Whitton JL: The role of B lymphocytes in coxsackievirus B3 infection. Am. J. Pathol. 155, 1205-1215 (1999).
146. Jarasch N, Martin U, Zell R, Wutzler P, Henke A: Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 12, 1633-1643 (2007).
147. Geller TJ, Condie D: A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J. Neurol. Sci. 129, 131-133 (1995).
148. Modlin JF, Bowman M: Perinatal transmission of coxsackievirus B3 in mice. J. Infect. Dis. 156, 21-25 (1987).
149. Nathanson N, McGann KA, Wilesmith J, Desrosiers RC, Brookmeyer R: The evolution of virus diseases: their emergence, epidemicity, and control. Virus Res. 29, 3-20 (1993).
150. Woodruff JF: Lack of correlation between neutralizing antibody production and suppression of coxsackievirus B-3 replication in target organs: evidence for involvement of mononuclear inflammatory cells in host defense. J. Immunol. 123, 31-36 (1979).
151. Chow LH, Beisel KW, McManus BM: Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66, 24-31 (1992).
152. Sato S, Tsutsumi R, Burke A et al.: Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions. J. Gen. Virol. 75, 2911-2924 (1994).
153. Schnurr DP, Schmidt NJ: Coxsackievirus B3 persistence and myocarditis in NFR nu/nu and +/nu mice. Med. Microbiol. Immunol. 173, 1-7 (1984).
154. Wong CY, Woodruff JJ, Woodruff JF: Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. I. Model and viral specificity. J. Immunol. 118, 1159-1164 (1977).
155. Guthrie M, Lodge PA, Huber SA: Cardiac injury in myocarditis induced by coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2+ cytolytic lymphocytes. Cell. Immunol. 88, 558-567 (1984).
156. Huber SA, Moraska A, Choate M: T cells expressing the gd T-cell receptor potentiate coxsackievirus B3-induced myocarditis. J. Virol. 66, 6541-6546 (1992).
157. Ramsingh AI, Lee WT, Collins DN, Armstrong LE: T cells contribute to disease severity during coxsackievirus B4 infection. J. Virol. 73, 3080-3086 (1999).
158. Blay R, Simpson K, Leslie K, Huber S: Coxsackievirus-induced disease. CD4+ cells initiate both myocarditis and pancreatitis in DBA/2 mice. Am. J. Pathol. 135, 899-907 (1989).
159. Opavsky MA, Penninger J, Aitken K et al.: Susceptibility to myocarditis is dependent on the response of ab T lymphocytes to coxsackieviral infection. Circ. Res. 85, 551-558 (1999).
160. Weinzierl AO, Rudolf D, Maurer D et al.: Identification of HLA-A 01-and HLA-A02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. J. Gen. Virol. 89, 2090-2097 (2008).
161. Jakel S, Kuckelkorn U, Szalay G et al.: Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis. Am. J. Pathol. 175, 510-518 (2009).
162. Voigt A, Jakel S, Textoris-Taube K et al.: Generation of in silico predicted coxsackievirus B3-derived MHC class I epitopes by proteasomes. Amino Acids 39(1), 243-255 (2009).
163. Varela-Calvino R, Skowera A, Arif S, Peakman M: Identification of a naturally processed cytotoxic CD8 T-cell epitope of coxsackievirus B4, presented by HLA-A2.1 and located in the PEVKEK region of the P2C nonstructural protein. J. Virol. 78, 13399-13408 (2004).
164. Callan MF, Tan L, Annels N et al.: Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
165. Miller JD, van der Most RG, Akondy RS et al.: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710-722 (2008).
166. Kemball CC, Harkins S, Whitton JL: Enumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infection. J. Virol. 82, 4331-4342 (2008).
167. Yue Y, Xu W, Hu L, Jiang Z, Xiong S: Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 386, 438-447 (2009).
168. Kemball CC, Harkins S, Whitmire JK, Flynn CT, Feuer R, Whitton JL: Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway. PLoS Path. 5, E1000618 (2009).
169. Slifka MK, Pagarigan RR, Mena I, Feuer R, Whitton JL: Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J. Virol. 75, 2377-2387 (2001).
170. Slifka MK, Whitton JL: Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat. Immunol. 2, 711-717 (2001).
171. Miller JP, Geng Y, Ng HL, Yang OO, Krogstad P: Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. Vaccine 27, 3992-4000 (2009).
172. Wessels E, Duijsings D, Notebaart RA, Melchers WJ, van Kuppeveld FJ: A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-Golgi transport. J. Virol. 79, 5163-5173 (2005).
173. De Jong AS, Visch HJ, de Mattia F et al.: The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J. Biol. Chem. 281, 14144-14150 (2006).
174. Wessels E, Duijsings D, Niu TK et al.: A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev. Cell 11, 191-201 (2006).
175. Wessels E, Duijsings D, Lanke KH et al.: Effects of picornavirus 3A proteins on protein transport and GBF1-dependent COP-I recruitment. J. Virol. 80, 11852-11860 (2006).
176. De Jong AS, de MF, van Dommelen MM et al.: Functional analysis of picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking. J. Virol. 82, 3782-3790 (2008).
177. Villadangos JA, Heath WR, Carbone FR: Outside looking in: the inner workings of the cross-presentation pathway within dendritic cells. Trends Immunol. 28, 45-47 (2007).
178. Mandl S, Sigal LJ, Rock KL, Andino R: Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc. Natl Acad. Sci. USA 95, 8216-8221 (1998).
179. Doedens JR, Kirkegaard K: Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 14, 894-907 (1995).
180. Deitz SB, Dodd DA, Cooper S, Parham P, Kirkegaard K: MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A. Proc. Natl Acad. Sci. USA 97, 13790-13795 (2000).
181. Dodd DA, Giddings TH Jr, Kirkegaard K: Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and b interferon secretion during viral infection. J. Virol. 75, 8158-8165 (2001).
182. Wahid R, Cannon MJ, Chow M: Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J. Virol. 79, 5988-5995 (2005).
183. Wahid R, Cannon MJ, Chow M: Dendritic cells and macrophages are productively infected by poliovirus. J. Virol. 79, 401-409 (2005).
184. Marttila J, Hyoty H, Vilja P et al.: T cell epitopes in coxsackievirus B4 structural proteins concentrate in regions conserved between enteroviruses. Virology 293, 217-224 (2002).
185. Huber S, Polgar J, Moraska A, Cunningham MW, Schwimmbeck P, Schultheiss P: T lymphocyte responses in CVB3-induced murine myocarditis. Scand. J. Infect. Dis. Suppl. 88, 67-78 (1993).
186. Halim SS, Ostrowski SE, Lee WT, Ramsingh AI: Immunogenicity of a foreign peptide expressed within a capsid protein of an attenuated coxsackievirus. Vaccine 19, 958-965 (2001).
187. Filippi CM, Estes EA, Oldham JE, von Herrath MG: Immunoregulatory mechanisms triggered by viral infections protect from Type 1 diabetes in mice. J. Clin. Invest. 119, 1515-1523 (2009).
188. Lee HK, Mattei LM, Steinberg BE et al.: In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 32, 227-239 (2010).
189. Huber SA, Graveline D, Newell MK, Born WK, OBrien RL: Vg1+ T cells suppress and Vg4+ T cells promote susceptibility to coxsackievirus B3-induced myocarditis in mice. J. Immunol. 165, 4174-4181 (2000).
190. Huber SA, Graveline D, Born WK, OBrien RL: Cytokine production by Vg+-T-cell subsets is an important factor determining CD4+ -Th-cell phenotype and susceptibility of BALB/c mice to coxsackievirus B3-induced myocarditis. J. Virol. 75, 5860-5869 (2001).
191. Huber S, Sartini D: T cells expressing the Vg1 T-cell receptor enhance virus-neutralizing antibody response during coxsackievirus B3 infection of BALB/c mice: differences in male and female mice. Viral Immunol. 18, 730-739 (2005).
192. Huber SA: CD1d expression on hemopoietic cells promotes CD4+ Th1 response in coxsackievirus B3 induced myocarditis. Virology 352, 226-236 (2006).
193. Huber SA, Budd RC, Rossner K, Newell MK: Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy. Ann. NY Acad. Sci. 887, 181-190 (1999).
194. Huber SA, Shi C, Budd RC: gd T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand. J. Virol. 76, 6487-6494 (2002).
195. Huber SA: Depletion of gd+ T cells increases CD4+ FoxP3 (T regulatory) cell response in coxsackievirus B3-induced myocarditis. Immunology 127, 567-576 (2009).
196. Heim A, Canu A, Kirschner P et al.: Synergistic interaction of interferon-b and interferon-g in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166, 958-965 (1992).
197. Kandolf R, Canu A, Hofschneider PH: Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J. Mol. Cell Cardiol. 17, 167-181 (1985).
198. Yiyun C, Yagi S, Schnurr D: Persistent infections by coxsackie virus B3. In: Pathogenesis and control of viral infections. Auti F (Ed.), Raven Press, NY, USA, 105-112, (1989).
199. Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M: Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J. Virol. 56, 651-654 (1985).
200. Tam PE, Schmidt AM, Ytterberg SR, Messner RP: Viral persistence during the developmental phase of coxsackievirus B1-induced murine polymyositis. J. Virol. 65, 6654-6660 (1991).
201. Tam PE, Schmidt AM, Ytterberg SR, Messner RP: Duration of virus persistence and its relationship to inflammation in the chronic phase of coxsackievirus B1-induced murine polymyositis. J. Lab. Clin. Med. 123, 346-356 (1994).
202. Tam PE, Messner RP: Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution. J. Virol. 73, 10113-10121 (1999).
203. Klingel K, Hohenadl C, Canu A et al.: Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl Acad. Sci. USA 89, 314-318 (1992).
204. Klingel K, Stephan S, Sauter M et al.: Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J. Virol. 70, 8888-8895 (1996).
205. Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU: Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 98, 450-457 (1998).
206. Wessely R, Klingel K, Santana LF et al.: Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J. Clin. Invest. 102, 1444-1453 (1998).
207. Kim KS, Tracy S, Tapprich W et al.: 5-terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J. Virol. 79, 7024-7041 (2005).
208. Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S: 5 terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375, 480-491 (2008).
209. Kim KS, Chapman NM, Tracy S: Replication of coxsackievirus B3 in primary cell cultures generates novel viral genome deletions. J. Virol. 82, 2033-2037 (2008).